Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Boehringer Ingelheim and OSE Immunotherapeutics Partner to Develop Novel Treatments for Cancer and Cardio-Renal-Metabolic Diseases

NextEdge Admin

23 May 2024

2 min 44 sec

Boehringer Ingelheim is expanding its anti-SIRPα immuno-oncology programs with two new projects aimed at developing first-in-class treatments. The first initiative involves broadening the therapeutic scope of partnered assets BI 765063 and BI 770371 to include cardiovascular-renal-metabolic (CRM) diseases, in addition to their Phase I clinical studies for advanced solid tumors. This amendment reflects the company’s commitment to addressing interconnected and co-existing diseases that collectively affect over one billion lives globally, causing approximately 20 million deaths annually.

Additionally, Boehringer Ingelheim is launching a new preclinical program through an asset acquisition from OSE Immunotherapeutics. This initiative focuses on developing immune-cell activating treatments using OSE’s cis-targeting anti-PD1/cytokine platform. These endeavors signify Boehringer Ingelheim’s dedication to advancing novel therapies for unmet patient needs, particularly in CRM diseases and cancer. The collaboration with OSE Immunotherapeutics aims to enrich the company’s pipeline with innovative treatment options.

Clive R. Wood, Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim, emphasized the significance of these developments in expanding their portfolio of CRM disease therapies and T-cell based anti-cancer therapies. The CEO of OSE Immunotherapeutics, Nicolas Poirier, expressed excitement about the partnership’s potential to introduce breakthrough therapies for CRM diseases and cancer patients.

Under the agreement, OSE Immunotherapeutics will receive EUR 13.5 million upfront payment and a potential near-term milestone payment of EUR 17.5 million for the acquisition of the cis-targeting anti-PD-1/cytokine asset. Additionally, Boehringer Ingelheim will make a one-time payment of EUR 25.3 million for partial royalty buy-out of the ongoing anti-SIRPα programs, with an option for further buy-out during development. The parties have retained milestone payments of up to €1.1 billion as per the initial agreement.